Search results
Results from the WOW.Com Content Network
ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease , including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections.
[16] 2013 saw the company complete its highest number of acquisitions with Lotus Tissue Repair, Inc. (lead compound, ABH001), [17] SARcode Bioscience Inc., [18] with the last being ViroPharma. Shire changed the name of ViroPharma to Shire Viropharma Inc. upon acquisition and on their final day of trading the company was valued at $3.3 billion. [19]
Shire plc is in the process of buying orphan drug-specialist ViroPharma for $4.2 billion, strengthening Shire's already robust commercial drug portfolio for rare diseases. The deal is expected to ...
Shire buys ViroPharma for $4.2 billionIrish pharmaceutical company Shire just announced that it will buy ViroPharma for Why You Should Keep an Eye on Shire, ViroPharma, and Novartis Today Skip to ...
What: Shares of ViroPharma Inc. , a. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to ...
ViroPharma (NAS: VPHM) carries $602 million of goodwill and other intangibles on its balance sheet. Sometimes goodwill, especially when it's excessive, can foreshadow problems down the road. Could ...
ViroPharma , the manufacturer of hereditary. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us. Mail. Sign in ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.